{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-26-013429","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2026-06-25T12:21:30+00:00","discovered_at":"2026-06-25T12:25:00.284094+00:00","generated_at":"2026-06-25T12:25:24.089564+00:00","sec_items":["7.01","5.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Merck KGaA to acquire Bio-Techne for $73/share in $11.3B deal","bullets":["Purchase price $73/share in cash; enterprise value $11.3B (EUR 9.9B); 36% premium to 1-month VWAP.","Expected to close by late 2026 / early 2027, subject to shareholder and regulatory approvals.","Annual cost synergies of ~EUR 140M expected fully realized by year 3 post-close.","Bio-Techne FY2025 net sales >$1.2B; ~3,000 employees; to operate as part of Merck KGaA Life Science.","Transaction approved by Bio-Techne Board and Merck corporate bodies; debt-funded with investment-grade credit maintained."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-26-013429","json":"https://secwatch.observer/filing/0001999371-26-013429.json","markdown":"https://secwatch.observer/filing/0001999371-26-013429.md","text":"https://secwatch.observer/filing/0001999371-26-013429.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000199937126013429/0001999371-26-013429-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000199937126013429/tech-8k_062526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T12:25:24.089564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}